معرفی
Mark Stevenson is a Research Fellow at the University of Oxford, based at the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), where he conducts critical research within the Thakker Group's Academic Endocrine Unit. His work bridges molecular oncology and clinical endocrinology to develop targeted therapies for endocrine-related cancers.
Education:
- BSc (Hons)
- PhD in cytogenetic analysis of Allium from the University of Birmingham
Research Interests: Dr. Stevenson specializes in endocrine tumor genetics, focusing on pancreatic, pituitary, and parathyroid cancers through models of hyperparathyroidism-jaw tumour syndrome and MEN1. His expertise spans molecular oncology—from PRMT5 in ovarian cancer to adenoviral vector development for prostate cancer—and viral oncology via HPV detection in cervical tissue. Current projects prioritize translating genetic insights into diagnostic tools and somatostatin-based therapeutics.
Recent Publications: His 2024-2025 output centers on calcium metabolism disorders (e.g., calcilytic therapy for ADH1, cinacalcet for hypercalcemia) and genetic mechanisms in neurodevelopmental/skeletal disorders. Key themes include AP2S1 variants, CRABP2-NFIX interactions, and GNAQ/GNA11 mosaicism, demonstrating a cohesive focus on targeted interventions for endocrine pathologies.
Scientific Awards:
- No specific awards documented in source material
Advising and Grants: No current PhD students or grant details are referenced; research appears embedded within the Thakker Group's infrastructure.
Research Environment: As a core member of Professor Rajesh Thakker's Academic Endocrine Unit at OCDEM, he leverages Oxford's translational research ecosystem to advance endocrine tumor models and therapeutic validation, with emphasis on clinical applicability.
